SMC is proud to announce that Chugai Pharmaceutical Co., Ltd. (JPN) has published the results of their study using our pre-clinical services with the STAM™ mouse in Pharmacol Res Perspect.

Title

Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non‐alcoholic steatohepatitis (NASH)

(Hada et al., Pharmacol Res Perspect., 2023)

In this study, they tested the potential of an SPT inhibitor, CH5169356, to suppress HSC activation and ameliorate liver fibrosis. In our STAM™ mouse, they observed that CH5169356 not only had an anti-fibrotic effect, but also alleviated liver inflammation, reducing ALT levels.

The STAM™ mouse is the world's first pathological mouse model to show the progression of NASH to liver cancer, and was developed here at SMC Laboratories. This model shows a similar pathology to human NASH (steatosis → NASH → liver fibrosis → HCC). Therefore, the STAM™ model has been used in many efficacy studies, as well as in basic research.

Also, more than 70 papers have been published using our STAM™ mouse and evaluations have been conducted on various targets and pathways related to NASH-HCC. If you are interested in our experience in evaluating targets of your compound, please contact us.

We would also be happy to arrange a Zoom meeting with our marketing and science team to briefly explain what services we offer and how we might be able to support your project.